CN103550740A - 一种治疗黄疸型肝炎的中药组合物及其应用 - Google Patents
一种治疗黄疸型肝炎的中药组合物及其应用 Download PDFInfo
- Publication number
- CN103550740A CN103550740A CN201310531490.3A CN201310531490A CN103550740A CN 103550740 A CN103550740 A CN 103550740A CN 201310531490 A CN201310531490 A CN 201310531490A CN 103550740 A CN103550740 A CN 103550740A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- radix
- chinese medicinal
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 239000010231 banlangen Substances 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims description 35
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 239000009636 Huang Qi Substances 0.000 claims description 6
- 241000545442 Radix Species 0.000 claims description 6
- 241000405217 Viola <butterfly> Species 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 240000007171 Imperata cylindrica Species 0.000 claims 1
- 241001598107 Imperata Species 0.000 abstract description 7
- 206010023126 Jaundice Diseases 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 210000000952 spleen Anatomy 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 4
- 244000025254 Cannabis sativa Species 0.000 abstract description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 2
- 244000197580 Poria cocos Species 0.000 abstract description 2
- 235000008599 Poria cocos Nutrition 0.000 abstract description 2
- 240000007164 Salvia officinalis Species 0.000 abstract description 2
- 244000273928 Zingiber officinale Species 0.000 abstract description 2
- 235000006886 Zingiber officinale Nutrition 0.000 abstract description 2
- 235000008397 ginger Nutrition 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 229940126673 western medicines Drugs 0.000 abstract description 2
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000006688 Telosma cordata Species 0.000 abstract 1
- 235000017352 Telosma cordata Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000012567 medical material Substances 0.000 description 13
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 206010007247 Carbuncle Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 201000007100 Pharyngitis Diseases 0.000 description 4
- 206010040943 Skin Ulcer Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 231100000019 skin ulcer Toxicity 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 2
- 239000003390 Chinese drug Substances 0.000 description 2
- 206010052369 Encephalitis lethargica Diseases 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- 241001278898 Glycyrrhiza inflata Species 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010043458 Thirst Diseases 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 201000002498 viral encephalitis Diseases 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000227129 Aconitum Species 0.000 description 1
- 241001671653 Aconitum carmichaelii Species 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 241000334154 Isatis tinctoria Species 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- SPPIIOPGDLITJE-VLQRKCJKSA-N diazanium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihy Chemical compound N.N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SPPIIOPGDLITJE-VLQRKCJKSA-N 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 208000010540 rapid respiration Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗黄疸型肝炎的中药组合物，涉及中药技术领域。其由如下重量份的中药材制备而成：茯苓25-35份、附子25-35份、丹参16-22份、川芎16-22份、黄芪16-22份、干姜10-16份、白茅根18-26份、大青叶18-26份、板蓝根18-26份、紫花地丁20-25份、甘草8-14份。本发明的中药组合物清热解毒，活血化瘀，健脾益气养阴，利胆退黄，兼顾全身，提高机体免疫力，配合西药治疗黄疸型肝炎的疗效显著。
Description
技术领域
本发明涉及一种治疗黄疸型肝炎的中药组合物，属于中药技术领域。
背景技术
黄疸型肝炎患者肝细胞损伤，肝内循环障碍，血液黏稠度高，血管紧张素Ⅱ增加，肝脏亚微结构改变，使毛细胆管内胆汁流动不畅，胆汁瘀积。TBil超过171 μmol/L，黄疸深，持续时间长，不易消退，常规护肝、利胆退黄，只是治标不治本，效果不满意。
发明内容
本发明根据传统中医理论，经过对药物组分的大量筛选、重组、尝试、又通过大量动物实验研究作出的。因此，本发明的目的在于提供了一种更加安全可靠的治疗黄疸型肝炎的中药组合物及其应用。
本发明的目的是这样实现的：
本发明一种治疗黄疸型肝炎的中药组合物，由如下重量份的中药材原料制备而成：茯苓25-35份、附子25-35份、丹参16-22份、川芎16-22份、黄芪16-22份、干姜10-16份、白茅根18-26份、大青叶18-26份、板蓝根18-26份、紫花地丁20-25份、甘草8-14份。
优选地，如上所述的治疗黄疸型肝炎的中药组合物，由如下重量份的中药材原料制备而成：茯苓28-32份、附子28-32份、丹参18-20份、川芎18-20份、黄芪18-20份、干姜12-14份、白茅根20-23份、大青叶20-23份、板蓝根20-23份、紫花地丁22-24份、甘草10-12份。
在本发明一个最优选的实施例中，其由如下重量份的中药材原料制备而成：茯苓30份、附子30份、丹参20份、川芎20份、黄芪20份、干姜12份、白茅根22份、大青叶22份、板蓝根22份、紫花地丁24份、甘草10份。
进一步优选地，所述的治疗黄疸型肝炎的中药组合物是口服制剂。
再进一步优选地，所述的治疗黄疸型肝炎的中药组合物是口服液、颗粒剂、片剂或胶囊剂。
通过大量临床试验研究发现，由上述中药材原料制备而成的药物组合物在治疗黄疸型肝炎方面具有显著的疗效，尤其特别适合重度黄疸型肝炎。因此，本发明的第二个目的在于提供一种医药新用途，即上述的中药组合物在制备治疗黄疸型肝炎的药物中的应用。
根据中医药史料记载，上述中药材原料具有如下药理活性和功能主治：
茯苓：具有渗湿利水，健脾和胃，宁心安神的功效。可治小便不利，水肿胀满，痰饮咳逆，呕逆，恶阻，泄泻，遗精，淋浊，惊悸，健忘等症。选用多孔菌科真菌茯苓Poria cocos （Schw.）Wolf 的干燥菌核。
附子：回阳救逆，补火助阳，散寒止痛。主治：用于阴盛格阳，大汗亡阳，吐泻厥逆，肢冷脉微，心腹冷痛，冷痢，脚气水肿，风寒湿痹，阳痿，宫冷，虚寒吐泻，阴寒水肿，阳虚外感，阴疽疮疡以及一切沉寒痼冷之疾。选自毛茛科植物乌头Aconitum carmichaelii Debx.的子根的加工品。
丹参：活血调经，祛瘀止痛，凉血消痈，清心除烦，养血安神。主治月经不调，经闭痛经， 症瘕积聚，胸腹刺痛，热痹疼痛，疮疡肿痛，心烦不眠；肝脾肿大，心绞痛。选自双子叶植物唇形科 Labiatae鼠尾草属植物丹参 Salvia miltiorrhiza Bge. 的干燥根及根茎。
川芎：活血行气，祛风止痛。用于安抚神经，正头风头痛，症瘕腹痛，胸胁刺痛，跌扑肿痛，头痛，风湿痹痛。选用伞形科植物川芎的根茎。
黄芪：有益气固表、敛汗固脱、托疮生肌、利水消肿之功效。用于治疗气虚乏力，中气下陷，久泻脱肛，便血崩漏，表虚自汗，痈疽难溃，久溃不敛，血虚萎黄，内热消渴，慢性肾炎，蛋白尿，糖尿病等。炙黄芪益气补中，生用固表托疮。
干姜：温中散寒，回阳通脉，燥湿消痰，温肺化饮。主治脘腹冷痛；呕吐；泄泻，亡阳厥逆；寒饮喘咳；寒湿痹痛。选用姜科植物姜Zingiber officinale Rosc.的干燥根茎。
白茅根：凉血，止血，清热，利尿。治热病烦渴，吐血，衄血，肺热喘急，胃热哕逆，淋病，小便不利，水肿，黄疸。选用禾本科植物白茅 Imperata cylindrical (L.) Beauv. var. major (Nees) C. E. Hubb. 的干燥根茎。
大青叶：清热，解毒，凉血，止血。治温病热盛烦渴，流行性感冒，急性传染性肝炎，菌痢，急性胃肠炎，急性肺炎，丹毒，吐血，衄血，黄疸，痢疾，喉痹，口疮，痈疽肿毒。选用十字花科植物菘蓝 Isatis indigotica Fort. 的干燥叶。
板蓝根：清热，解毒，凉血，利咽。主治：温毒发斑；高热头痛；大头瘟疫；舌绛紫暗，烂喉丹痧；丹毒；痄腮；喉痹；疮肿、痈肿；水痘；麻疹；肝炎；流行性感冒，流脑，乙脑，肺炎，神昏吐衄，咽肿，火眼，疮疹；可防治流行性乙型脑炎、急慢性肝炎、流行性腮腺炎、骨髓炎。选用十字花科植物菘篮和草大青的根。
紫花地丁：清热解毒，凉血消肿。主治黄疸、痢疾、乳腺炎、目赤肿痛、咽炎；外敷治跌打损伤、痈肿、毒蛇咬伤等。选用紫花地丁的干燥全草。
甘草：补脾益气，清热解毒，祛痰止咳，缓急止痛，调和诸药。用于脾胃虚弱，倦怠乏力，心悸气短，咳嗽痰多，脘腹、四肢挛急疼痛，痈肿疮毒，缓解药物毒性、烈性。选用为双子叶植物豆科 Leguminosae甘草 Glycyrrhiza uralensis Fisch. ，胀果甘草 G. inflata Bat.， 或光果甘草 G. glabra L. 的根及根茎。
将上述各中药材制备成本发明的复方口服液的制备方法，包括如下步骤：称取清洗干净且干燥的药材合并，加水煎煮两次，合并煎液，减压浓缩至70℃时相对密度为1.15-1.20，加乙醇使含醇量的体积百分比达75-85%，搅拌，静置，过滤，滤液减压浓缩至70℃时相对密度为1.25-1.30并回收乙醇得浓缩液，将浓缩液加水及辅料配制成口服液。
与现有技术相比，本发明的中药组合物清热解毒，活血化瘀，健脾益气养阴，利胆退黄，兼顾全身，提高机体免疫力，配合西药治疗黄疸型肝炎的疗效显著，达到了西药治标中药治本的目的，效果满意。
具体实施方式
下面通过实施例进一步说明本发明。本发明的实施例仅仅是用于说明本发明，而不是对本发明的限制，在本发明的构思前提下对本发明制备方法的简单改进都属于本发明要求保护的范围。
实施例1
生药处方：茯苓30份、附子30份、丹参20份、川芎20份、黄芪20份、干姜12份、白茅根22份、大青叶22份、板蓝根22份、紫花地丁24份、甘草10份。
制备方法：称取上述处方量的药材合并，加水煎煮两次，第一次加水为药材重量的10倍量，煎煮2h，第二次加水为药材重量的8倍量，煎煮1.5h，合并煎液，0.08MPa、70℃下减压浓缩至70℃时相对密度为1.15，加95%(v/v)乙醇使含醇量达75%(v/v)， 搅拌， 静置过夜，过滤，滤液在0.08MPa、65℃条件下减压浓缩成至65℃时相对密度为1.30，加水及蔗糖配制成口服液。
实施例2
生药处方：茯苓25份、附子33份、丹参22份、川芎16份、黄芪22份、干姜16份、白茅根18份、大青叶25份、板蓝根20份、紫花地丁22份、甘草14份。
制备方法：称取上述处方量的药材合并，加水煎煮两次，第一次加水为药材重量的10倍量，煎煮2h，第二次加水为药材重量的8倍量，煎煮1.5h，合并煎液，0.08MPa、70℃下减压浓缩至70℃时相对密度为1.15，加95%(v/v)乙醇使含醇量达85%(v/v)， 搅拌， 静置过夜，过滤，滤液在0.08MPa、65℃条件下减压浓缩成至65℃时相对密度为1.30，加水及蔗糖配制成口服液。
实施例3
生药处方：茯苓32份、附子26份、丹参16份、川芎20份、黄芪16份、干姜12份、白茅根26份、大青叶18份、板蓝根26份、紫花地丁25份、甘草10份。
制备方法：称取上述处方量的药材合并，加水煎煮两次，第一次加水为药材重量的10倍量，煎煮2h，第二次加水为药材重量的8倍量，煎煮1.5h，合并煎液，0.08MPa、70℃下减压浓缩至70℃时相对密度为1.20，加95%(v/v)乙醇使含醇量达80%(v/v)， 搅拌， 静置过夜，过滤，滤液在0.08MPa、65℃条件下减压浓缩成至65℃时相对密度为1.30，加水及蔗糖配制成口服液。
实施例4 本发明中药组合物对重度黄疸型肝炎患者的影响
中药样品制备：称取茯苓30份、附子30份、丹参20份、川芎20份、黄芪20份、干姜12份、白茅根22份、大青叶22份、板蓝根22份、紫花地丁24份和甘草10份，将上述处方量的药材合并，加水煎煮两次，第一次加水为药材重量的10倍量，煎煮2h，第二次加水为药材重量的8倍量，煎煮1.5h，合并煎液，0.08MPa、70℃下减压浓缩至70℃时相对密度为1.15，加95%(v/v)乙醇使含醇量达75%(v/v)， 搅拌， 静置过夜，过滤，滤液在0.08MPa、65℃条件下减压浓缩成至65℃时相对密度为1.30，即可。
52例患者，男34例，女18例，年龄最小17岁，最大60岁，病程最短2d，最长16d。所有患者诊断均符合2000年西安会议修订的病毒性肝炎防治诊断标准，并伴有谷丙转氨酶(ALT)升高，血清总胆红素(TBil)超过171μmol/L。所有患者随机分为对照组(26例)和中药组(26例)，两组在性别、年龄、病程等方面没有显著性差异。
对照组单纯西药治疗，即甘利欣200mg/d，门冬氨酸鸟氨酸2.5g/d对症护肝，15d为1个疗程，连续用药2个疗程。根据肝功能情况及时调整用药剂量。中药组在对照组基础上加上述中药治疗，患者每日早晚口服20mL，连续服用一个月。治疗结束后，按如下疗效评定标准统计治疗结果：
显效：主要症状消失，肝功能正常，TBil恢复到17.1μmol/L以下；
有效：主要症状明显好转，TBil降至治疗前的1/3～1/2，ALT、r-GT明显降低；
无效：症状体征无改善，肝功能无变化，甚至病情加重。
表1 两组患者总体疗效比较
通过本实验可以看出，本发明中西药结合治疗重度黄疸型肝炎，标本兼治，总有效率达到88.5％，效果满意，值得临床上推广。
Claims (6)
1.一种治疗黄疸型肝炎的中药组合物，其特征在于：所述的中药组合物由如下重量份的中药材原料制备而成：茯苓25-35份、附子25-35份、丹参16-22份、川芎16-22份、黄芪16-22份、干姜10-16份、白茅根18-26份、大青叶18-26份、板蓝根18-26份、紫花地丁20-25份、甘草8-14份。
2.根据权利要求1所述的治疗黄疸型肝炎的中药组合物，其特征在于：所述的中药组合物由如下重量份的中药材原料制备而成：茯苓28-32份、附子28-32份、丹参18-20份、川芎18-20份、黄芪18-20份、干姜12-14份、白茅根20-23份、大青叶20-23份、板蓝根20-23份、紫花地丁22-24份、甘草10-12份。
3.根据权利要求1所述的治疗黄疸型肝炎的中药组合物，其特征在于：所述的中药组合物由如下重量份的中药材原料制备而成：茯苓30份、附子30份、丹参20份、川芎20份、黄芪20份、干姜12份、白茅根22份、大青叶22份、板蓝根22份、紫花地丁24份、甘草10份。
4.根据权利要求1或2或3所述的治疗黄疸型肝炎的中药组合物，其特征在于：所述中药组合物为口服制剂。
5.根据权利要求3所述的治疗黄疸型肝炎的中药组合物，其特征在于：所述中药组合物为口服液、颗粒剂、片剂或胶囊剂。
6.权利要求1或2或3所述的药物组合物在制备治疗黄疸型肝炎的药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310531490.3A CN103550740B (zh) | 2013-11-01 | 2013-11-01 | 一种治疗黄疸型肝炎的中药组合物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310531490.3A CN103550740B (zh) | 2013-11-01 | 2013-11-01 | 一种治疗黄疸型肝炎的中药组合物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103550740A true CN103550740A (zh) | 2014-02-05 |
| CN103550740B CN103550740B (zh) | 2015-06-10 |
Family
ID=50005213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310531490.3A Active CN103550740B (zh) | 2013-11-01 | 2013-11-01 | 一种治疗黄疸型肝炎的中药组合物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103550740B (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1781546A (zh) * | 2004-11-30 | 2006-06-07 | 尹灵芝 | 肝胆胃复康合剂及其制备方法 |
| CN1814211A (zh) * | 2005-11-27 | 2006-08-09 | 干宝善 | 治疗急性黄疸型肝炎的中草药汤剂及制备方法 |
| CN102228648A (zh) * | 2011-06-27 | 2011-11-02 | 武红莲 | 用于治疗黄疸型肝炎的中药组合物 |
| CN102335243A (zh) * | 2011-10-17 | 2012-02-01 | 潘月玲 | 一种治疗黄疸型肝炎的中药组合物 |
| CN103120746A (zh) * | 2011-11-21 | 2013-05-29 | 成都市湔江制药厂 | 一种治疗病毒性肝炎的药物 |
-
2013
- 2013-11-01 CN CN201310531490.3A patent/CN103550740B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1781546A (zh) * | 2004-11-30 | 2006-06-07 | 尹灵芝 | 肝胆胃复康合剂及其制备方法 |
| CN1814211A (zh) * | 2005-11-27 | 2006-08-09 | 干宝善 | 治疗急性黄疸型肝炎的中草药汤剂及制备方法 |
| CN102228648A (zh) * | 2011-06-27 | 2011-11-02 | 武红莲 | 用于治疗黄疸型肝炎的中药组合物 |
| CN102335243A (zh) * | 2011-10-17 | 2012-02-01 | 潘月玲 | 一种治疗黄疸型肝炎的中药组合物 |
| CN103120746A (zh) * | 2011-11-21 | 2013-05-29 | 成都市湔江制药厂 | 一种治疗病毒性肝炎的药物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103550740B (zh) | 2015-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102940851A (zh) | 一种用于颈椎病的中药分散片及其制备方法 | |
| CN103784890A (zh) | 一种治疗骨病的中药组合物 | |
| CN103638451A (zh) | 一种治疗慢性肝炎的中药及其制备方法 | |
| CN101912567B (zh) | 治疗慢性心肌炎的中药 | |
| CN116585441A (zh) | 一种用于防治新型冠状病毒感染的中药组合物及其制备方法 | |
| CN103272136B (zh) | 一种治疗妇女更年期综合症中药 | |
| CN104940418A (zh) | 一种治疗肝炎的纯中药丸及其制备方法 | |
| CN102743703B (zh) | 一种治疗颈椎病的药物及其制备方法 | |
| CN104337989A (zh) | 一种含鹅不食草和乳香的治疗痛风的中药组合物 | |
| CN102552520B (zh) | 一种活血止痛胶囊及制备工艺和应用 | |
| CN104435567A (zh) | 一种含绞股蓝的治疗痛风的中药组合物 | |
| CN103800840A (zh) | 一种治疗颈椎病的中药口服液 | |
| CN103041362B (zh) | 一种治疗风湿、类风湿的药物及其制备方法 | |
| CN103550740B (zh) | 一种治疗黄疸型肝炎的中药组合物及其应用 | |
| CN105535855A (zh) | 一种治疗乙型肝炎的中药组合物及其制备方法 | |
| CN105126034A (zh) | 一种用于治疗冠心病的药物制剂 | |
| CN104147277A (zh) | 一种治疗重症肌无力的中药制剂及制备方法 | |
| CN109528943A (zh) | 一种抗流感中药高浓缩丸的配方及制备 | |
| CN103285130B (zh) | 治疗肝癌的中药组合物及其制备方法 | |
| CN103212033B (zh) | 一种治疗病毒性肝炎的药物组合物 | |
| CN102764325B (zh) | 祛湿除痛中药组合物 | |
| CN101983712A (zh) | 冠心病的新型治疗药物 | |
| CN105943967A (zh) | 一种含有蕲蛇的祛湿抗肿瘤中药组合物及其制备方法 | |
| CN105412244A (zh) | 一种治疗妇科宫颈炎的中药组合物 | |
| CN105535188A (zh) | 一种养肝护肝的中药 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170425 Address after: The 9 group and the Yin Yang Zhen Feng Cun Qidong, Jiangsu city of Nantong province 226200 Patentee after: Qidong Feng Wu agricultural cooperatives Address before: 276017 Linyi hi tech Industrial Development Zone, innovation building, building 2, Di Di, Shandong science and Technology Information Service Center Patentee before: Yang Xianhua |
|
| TR01 | Transfer of patent right |